Andreas A Argyriou
Overview
Explore the profile of Andreas A Argyriou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
2444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vikelis M, Rikos D, Argyriou A, Dermitzakis E, Andreou A, Russo A
Expert Rev Neurother
. 2025 Jan;
:1-16.
PMID: 39884968
Introduction: When a first anti-CGRP monoclonal antibody (anti-CGRP mAb) fails, switching to a different anti-CGRP mAb is an option often considered, despite the fact that this approach is not yet...
2.
Dermitzakis E, Rikos D, Vikelis M, Xiromerisiou G, Zisopoulou S, Rallis D, et al.
Brain Sci
. 2025 Jan;
14(12.
PMID: 39766367
The present open-label multicenter pilot study sought to prospectively evaluate the efficacy and safety of rimegepant in treating migraine attacks. The primary endpoint was pain freedom at two hours post-dose,...
3.
Velasco R, Argyriou A, Cornblath D, Bruna P, Alberti P, Rossi E, et al.
Eur J Neurol
. 2024 Sep;
31(12):e16457.
PMID: 39282967
Background And Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is perceived differently by patients and physicians, complicating its assessment. Current recommendations advocate combining clinical and patient-reported outcomes measures, but this approach can...
4.
Argyriou A, Dermitzakis E, Xiromerisiou G, Rikos D, Rallis D, Soldatos P, et al.
Expert Rev Neurother
. 2024 Sep;
24(11):1119-1126.
PMID: 39279446
Objective: This post-hoc analysis of data extracted from a prospective study aimed to explore for the first time if the efficacy of fremanezumab in preventing difficult-to-treat migraine, according to ICHD-III,...
5.
Velasco R, Marco C, Domingo-Domenech E, Stradella A, Santos C, Laquente B, et al.
Eur J Neurol
. 2024 Jul;
31(9):e16369.
PMID: 38952074
Background And Purpose: A real-time biomarker in chemotherapy-induced peripheral neurotoxicity (CIPN) would be useful for clinical decision-making during treatment. Neurofilament light chain (NfL) can be detected in blood in the...
6.
Vikelis M, Rikos D, Argyriou A, Papachristou P, Rallis D, Karapanayiotides T, et al.
Expert Rev Neurother
. 2024 Jun;
24(8):815-826.
PMID: 38870024
Background: To identify the preferences and perceptions of migraine patients for acute and preventive treatment options and to investigate which treatment outcomes are the most important. Design And Methods: The...
7.
Dermitzakis E, Argyriou A, Bilias K, Barmpa E, Liapi S, Rikos D, et al.
J Clin Med
. 2024 May;
13(10).
PMID: 38792309
The Greek Society of Migraine and Headache Patients conducted its third in-line population web-based survey in 2023 to ascertain if the burden of the disease and the patients' satisfaction with...
8.
Rikos D, Vikelis M, Dermitzakis E, Soldatos P, Rallis D, Rudolf J, et al.
J Clin Med
. 2024 Apr;
13(7).
PMID: 38610729
Phase II/III randomized clinical trials (RCTs) are vulnerable to many types of bias beyond randomization. Insights into the reporting quality of RCTs involving migraine patients treated with monoclonal antibodies targeting...
9.
Argyriou A, Dermitzakis E, Rikos D, Xiromerisiou G, Soldatos P, Litsardopoulos P, et al.
Toxins (Basel)
. 2024 Feb;
16(2).
PMID: 38393184
Background: We primarily aimed to ascertain whether treatment with OnabotulinumtoxinA (BoNTA) might influence the extent of the interictal burden and cutaneous allodynia in patients with chronic migraine (CM). Methods: Seventy...
10.
Alberti P, Argyriou A, Bruna J, Damaj M, Faithfull S, Harding A, et al.
Support Care Cancer
. 2024 Feb;
32(3):175.
PMID: 38381222
No abstract available.